University Medical Center Gottingen has also committed to purchase a
second SoftScan system, fully upgraded for use in screening with
molecular probes, subject to grant funding

MONTREAL, CANADA--(Marketwire - May 12, 2009) - ART Advanced Research
Technologies Inc. ("ART") (TSX: ARA), a Canadian medical device
company and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, announced today that it has
received a purchase order for one of its SoftScan® breast imaging
systems from the Department of Radiology of the University Medical
Center Gottingen, in Germany.

"We are very proud to see that the interdisciplinary molecular
imaging group of the University of Gottingen, in cooperation with the
Max-Planck-Institute of Experimental Medicine, has chosen our
SoftScan breast imaging system to conduct world-class research in the
field of translational oncology and radiology and to have them among
our growing base of clients," said Sebastien Gignac, Chairman & CEO
of ART. "The fact that the Interdisciplinary Imaging Group Gottingen,
in which radiologists, oncologists, physicists, molecular biologists,
imaging scientists and chemists work in close collaboration, has
ordered a SoftScan system is testimony to the power of our technology
to address the needs of leading researchers in the field of
oncology," added Mr. Gignac.

The University Medical Center Gottingen Department of Diagnostic
Radiology already owns an ART Optix® preclinical imaging system and
plans on using the SoftScan system to further its development of
cancer monitoring while exploring new therapies. In a second phase of
the research, the Interdisciplinary Imaging Group Gottingen intends
to use NIR (near-infrared) fluorescent biomarkers to monitor and
treat specific cancers as well as identify metastatic propagation
mechanisms. "We feel that ART's time domain technology will allow us
to find novel imaging diagnostics for individual therapies to mark
further advances towards a more personalized medicine in oncology,"
said Dr. Christoph Engelke, Department of Diagnostic Radiology, and
Professor Frauke Alves, Department of Hematology and Oncology,
University Medical Center Gottingen.

About the SoftScan® system

The SoftScan® optical breast imaging system has been designed first
as a complementary diagnostic tool to mammography, with ultimate uses
in the detection and treatment monitoring of breast cancer. Its
non-invasive, painless approach uses time-domain optical imaging
technology, which enables clinicians to better locate and
characterize breast tumors as benign or malignant and could provide
faster assessment of therapeutic effectiveness. Unlike mammography
whose use must be strictly limited, the SoftScan system emits no
radiation and can be safely used as often as needed to monitor
patients. The device was created and developed by ART Advanced
Research Technologies Inc., and has obtained market clearance for its
commercialization in Canada and in Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix® optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan® optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra® line
of molecular imaging contrast products provides image enhancement for
a wide range of preclinical Micro CT applications allowing scientists
to see greater detail in their imaging studies, with potential
extension into other major imaging modalities. ART is commercializing
some of these products in a global strategic alliance with GE
Healthcare, a world leader in mammography and imaging. ART's shares
are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca.

About the University of Gottingen

Founded in 1737, the Georg-August University of Gottingen is a
research university of international renown with strong focuses in
research-led teaching. One of the largest national higher education
institutions, it is officially rated amongst the nine German elite
institutions of higher education. Gottingen combines an impressive
number of analytical and biomedical research institutes and
university faculties -including the University Medical Center
Gottingen, three Max-Planck Institutes, the German Primate Center,
the Gottingen Laser Institute and the European Neuroscience
Institute-and has been linked with more Nobel Prizes than any other
city in Europe, excluding Stockholm. This high science density
provides a unique expertise and equipment landscape, and facilitates
integrated multidisciplinary research. For more information, please
visit the University of Gottingen web site at
http://www.uni-goettingen.de/en.

This press release may contain forward-looking statements subject to
risks and uncertainties that would cause actual events to differ
materially from expectations. These risks and uncertainties are
described in ART's most recent Annual Information Form and the
financial statements for the year ended December 31, 2008, available
on SEDAR (www.sedar.com).

Contacts:
ART Advanced Research Technologies Inc.
Jacques Bedard
Chief Financial Officer
514-832-0777
jbedard@art.ca

ART Advanced Research Technologies Inc.
Mario Khayat
Vice President, Optical Products
514-832-0777
mkhayat@art.ca
www.art.ca


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.